Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hansa Biopharma AB's change in inventory for the quarter that ended in Jun. 2026 was kr0.0 Mil. It means Hansa Biopharma AB's inventory
stayed the same
from Mar. 2026 to Jun. 2026 .
Hansa Biopharma AB's change in inventory for the fiscal year that ended in Dec. 2025 was kr0.0 Mil. It means Hansa Biopharma AB's inventory
stayed the same
from Dec. 2024 to Dec. 2025 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Hansa Biopharma AB's Days Inventory for the quarter that ended in Jun. 2026 was 28.61.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Hansa Biopharma AB's Inventory Turnover for the quarter that ended in Jun. 2026 was 3.19.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hansa Biopharma AB's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.15.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hansa Biopharma AB's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB Change In Inventory Related Terms
Hansa Biopharma AB Change In Inventory Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of kr0.0 Mil mean?
Hansa Biopharma AB (CHIX:HNSAS) has a Change In Inventory of kr0.0 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Change In Inventory too high?
Hansa Biopharma AB's current Change In Inventory is kr0.0 Mil. Overall, Hansa Biopharma AB has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Change In Inventory compare to VRTX and REGN?
Hansa Biopharma AB's Change In Inventory of kr0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Change In Inventory is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (CHIX:HNSAS) has a current Change In Inventory of kr0.0 Mil. The stock's GF Value™ is kr16.59, compared to a current price of kr25.64 — trading 54.6% above its estimated fair value. The current Change In Inventory is kr0.0 Mil. Hansa Biopharma AB's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Hansa Biopharma AB (CHIX:HNSAS), the current Change In Inventory is kr0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (CHIX:HNSAS) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr25.64 is trading 54.6% above its estimated GF Value™ of kr16.59.
Key valuation signals for CHIX:HNSAS:
Change In Inventory: kr0.0 Mil
GF Value™: kr16.59 vs. price of kr25.64 (54.6% above fair value)
No single metric tells the full story. See the CHIX:HNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
49GF Score
Get the complete analysis for CHIX:HNSAS
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:HNSAS has been successfully added to your 
